A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation - Simeone, Ester; Scognamiglio, Giosuè; Capone, Mariaelena; Giannarelli, Diana; Grimaldi, Antonio M.; Mallardo, Domenico; Madonna, Gabriele; Curvietto, Marcello; Esposito, Assunta; Sandomenico, Fabio; Sabbatino, Francesco; Bayless, Nicholas L.; et al. (Journal of translational medicine, 2021)
Keywords: Adult; Adverse events; Animals; Antigens; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Azetidines; Biomarkers; Biopsy; BRAF inhibitor; Cell Cycle Proteins; Cloning; Drug therapy; Drug therapy, Combination; Gas1 protein; Genetic aspects; GPI-Linked Proteins; Humans; Immune response; Interferon; Interferons; Kinases; Lymphocytes; Malignant melanoma; MAP kinase; Melanoma; Melanoma - drug therapy; Melanoma - genetics; Metastasis; Mice; Mutation; Mutation - genetics; Peginterferon alfa-2a; Piperidines; Proto-Oncogene Proteins B-raf - genetics; Skin cancer; Skin Neoplasms - drug therapy; Testing; Vemurafenib; Vemurafenib - therapeutic use; α-Interferon; Italy; BRAF inhibitor; MAP kinase; Interferon; Malignant melanoma